Everything below concerns cyclic heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
==== United States ==== The first approved PSMA imaging agent was indium-111 (111In) capromab pendetide (branded Prostascint). It received Food and Drug Administration (FDA) approval in 1996. However, the agent had poor sensitivity and saw little widespread use. The first PET PSMA imaging agent, 68Ga-PSMA-11, was approved by the FDA in 2020. Listed indications include suspected metastasis prior to initial treatment, and recurrence of prostate cancer (based on elevated serum prostate-specific antigen (PSA) level). This was followed by two further 68Ga-PSMA-11 agents in 2021 and 2022 (branded Illucix and Locametz). Listed indications for Lucametz additionally includes selection of patients prior to 177Lu-PSMA radionuclide therapy. An 18F-PSMA agent (18F-DCFPyL) (branded Pylarify) was approved by the FDA in 2021. Indications are as for 68Ga-PSMA-11. Another 18F-PSMA agent (18F-rhPSMA-7.3) (branded Posluma) was approved by the FDA in 2023.
In the article Cosmology and Civilizations published in 1997, Kardashev reiterates the need to carefully observe astronomical objects with strong radiation in order to detect supercivilizations. However, the discovery of a civilization at a stage of development similar to ours is unlikely. The existence of such supercivilizations is made possible by the fact that life on Earth is recent compared to the age of the Universe (8×109 years before the formation of the Solar System). He then examines the conditions for the appearance of life on cosmological time scales. Assuming the rate of evolution of life on Earth and considering the age of the Universe, it is reasonable to assume that a civilization could have reached our level of technological development in 6×109 years. Such civilizations can be observed in nearby regions, since the farther away we observe, the younger the objects are. Recent discoveries of sources of intense radiation deadly to life show that life could have flourished under cover for the time necessary for its appearance and maintenance. Another argument for the possibility of a very old supercivilization is that most of the objects that could be megastructures have not yet been discovered and mapped. In addition, 95% of the matter remains invisible or can only be inferred by the gravitational influence it produces. According to Kardashev, it is essential to focus our search tools on new objects radiating at a wavelength of a few microns to a few millimeters, and at a temperature of 3 to 300 K, which is characteristic of large structures of solid matter.
Ayyadurai garnered 3.39% of the vote as an independent candidate in the 2018 U.S. Senate election in Massachusetts, and ran for the Republican Party nomination in the 2020 U.S. Senate election in Massachusetts but lost to Kevin O'Connor in the primary. After the election, he promoted false claims of election fraud. In 2024, Ayyadurai launched a campaign to be the president of the United States. However, because he is not a natural-born American citizen, he is ineligible to serve as president.
"Bromantane [does] not concede well-known psychostimulant of phenylalkylamine structure and its analogs (amphetamine, [mesocarb], [methylphenidate], etc.) by specific activity. In contrast, bromantane has neither addictive potential nor reveals redundant and exhausting activation of sympaticoadrenergic system, or decelerates the restoring of work capacity at preventive application before forthcoming activity in complicated conditions (hypoxia, high environmental temperature, physical overfatigue, emotional stress, etc.). Bromantane has no prohypoxic activity." "The use of the drug, in contrast to the action of a typical psychostimulant, is not associated with the phenomenon of hyperstimulation and causes no consequences such as functional exhaustion of the body." "Bromantane administration in therapeutic doses is characterized by the almost full absence of side effects including manifestations of withdrawal syndrome and hyperstimulation." "[Bromantane] has low peripheral sympathomimetic effects. Moreover, no signs of [bromantane] dependence and withdrawal symptoms were found." Bromantane is well tolerated and elicits few side effects (including peripheral sympathomimetic effects and hyperstimulation), does not appear to produce tolerance or dependence, has not been associated with withdrawal symptoms upon discontinuation, and displays an absence of addiction potential, contrary to typical stimulants. In accordance with human findings, animals exposed to bromantane for extended periods of time do not appear to develop tolerance or dependence.
Sources: en.wikipedia.org
==== Coal ==== Coal contains a small amount of radioactive uranium, barium, thorium, and potassium, but, in the case of pure coal, this is significantly less than the average concentration of those elements in the Earth's crust. The surrounding strata, if shale or mudstone, often contain slightly more than average and this may also be reflected in the ash content of 'dirty' coals. The more active ash minerals become concentrated in the fly ash precisely because they do not burn well. The radioactivity of fly ash is about the same as black shale and is less than phosphate rocks, but is more of a concern because a small amount of the fly ash ends up in the atmosphere where it can be inhaled. According to U.S. National Council on Radiation Protection and Measurements (NCRP) reports, population exposure from 1000-MWe power plants amounts to 490 person-rem/year for coal power plants, 100 times as great as nuclear power plants (4.8 person-rem/year). The exposure from the complete nuclear fuel cycle from mining to waste disposal is 136 person-rem/year; the corresponding value for coal use from mining to waste disposal is "probably unknown".
Low-density lipoprotein receptor-related protein 5 is a protein that in humans is encoded by the LRP5 gene. LRP5 is a key component of the LRP5/LRP6/Frizzled co-receptor group that is involved in canonical Wnt pathway. Mutations in LRP5 can lead to considerable changes in bone mass. A loss-of-function mutation causes osteoporosis pseudoglioma syndrome with a decrease in bone mass, while a gain-of-function mutation causes drastic increases in bone mass.
=== Planned/unfinished designs === Focke-Wulf Fw 42 – twin-engined medium bomber project developed from the F 19, 1933. Focke-Wulf Ta 183 Huckebein – design for a jet-engined fighter, 1942. Focke-Wulf Fw 206 – planned commercial aircraft, 1940. Focke-Wulf Fw 238 – long-range bomber project (RLM airframe number 8-238 already used by Blohm und Voss) Focke-Wulf Fw 249 – large transport aircraft project; officially designated as Project 195. Focke-Wulf Fw 250 – twin-engine jet fighter project Focke-Wulf Fw 252 – single engine jet fighter Focke-Wulf Ta 254 – proposed version of the Ta 154 fighter. Focke-Wulf Fw 259 Frontjäger (concept) Focke-Wulf Fw 260 – 1960s VTOL airliner proposal Focke-Wulf Fw 261 – four-engine bomber/reconnaissance/U-boat support aircraft project Focke-Wulf Ta 283 – interceptor fighter project Focke-Wulf Fw 300 – proposed long-range version of Fw 200, 1941-1942. Focke-Wulf Ta 400 – Amerikabomber design competitor, never built, 1943. Focke-Wulf Fw P.03.10206 – series of long-range strategic bomber projects, 1944. Focke-Wulf Fw P.03.10221-15 – large capacity strategic transport, 1941. Focke-Wulf Fw P.03.10025 – A 1944 design with a swept wing, a forward-swept V-tail, and two pusher propellers at the rear. Focke-Wulf Fw 03.10251 – series of jet-engined night and bad weather fighters Focke-Wulf Fighter Project w/BMW803 – A 1941 design with a connected twin-boom tail, slightly swept-back wings, and two pusher propellers at the rear.
This allowed the development of thoracic surgery, which had previously been vexed by the pendelluft problem in which the bad lung being operated on inflated with patient exhalation due to the loss of vacuum with the thorax being open to the atmosphere. Eventually by early 1980s double lumen endotracheal tubes made out of clear plastic enabled anesthesiologists to selectively ventilate one lung while using flexible fiberoptic bronchoscopy to block off the diseased lung and prevent cross contamination. One early device, the copper kettle, was developed by Dr. Lucien E. Morris at the University of Wisconsin. Sodium thiopental, the first intravenous anesthetic, was synthesized in 1934 by Ernest H. Volwiler (1893–1992) and Donalee L. Tabern (1900–1974), working for Abbott Laboratories. It was first used in humans on 8 March 1934 by Ralph M. Waters in an investigation of its properties, which were short-term anesthesia and surprisingly little analgesia. Three months later, John Silas Lundy started a clinical trial of thiopental at the Mayo Clinic at the request of Abbott Laboratories. Volwiler and Tabern were awarded U.S. Patent No. 2,153,729 in 1939 for the discovery of thiopental, and they were inducted into the National Inventors Hall of Fame in 1986. In 1939, the search for a synthetic substitute for atropine culminated serendipitously in the discovery of meperidine, the first opiate with a structure altogether different from that of morphine.
== Philosophy == Adorno's work sets out from a central insight he shares with all early 20th-century avant-garde art: the recognition of what is primitive in ourselves and the world itself. Neither Picasso's fascination with African sculpture nor Mondrian's reduction of painting to its most elementary component—the line—is comprehensible outside this concern with primitivism, which Adorno shared with the century's most radical art. At that time, the Western world, beset by world wars, colonialist consolidation, and accelerating commodification, sank into the very barbarism civilization had prided itself in overcoming. According to Adorno, society's self-preservation had become indistinguishable from the socially sanctioned self-sacrifice of "primitive" people, the primitive aspects of the ego, and those primitive, mimetic desires found in imitation and sympathy. Adorno's theory proceeds from an understanding of this primitive quality of reality that seeks to counteract whatever aims either to repress this primitive aspect or to further those systems of domination set in place by this return to barbarism. From this perspective, Adorno's writings on politics, philosophy, music, and literature are a lifelong critique of the ways in which each tries to justify self-mutilation as the necessary price of self-preservation.
Sources: en.wikipedia.org
== Identification == Identifying what is and is not a mushroom requires a basic understanding of their macroscopic structure. Most are basidiomycetes and gilled. Their spores, called basidiospores, are produced on the gills and fall in a fine rain of powder from under the caps as a result. At the microscopic level, the basidiospores are shot off basidia and then fall between the gills in the dead air space. As a result, for most mushrooms, if the cap is cut off and placed gill-side-down overnight, a powdery impression reflecting the shape of the gills (or pores, or spines, etc.) is formed (when the fruit body is sporulating). The color of the powdery print, called a spore print, is useful in both classifying and identifying mushrooms. Spore print colors include white (most common), brown, black, purple-brown, pink, yellow, and creamy, but almost never blue, green, or red.
Elevated creatine kinase (CK) levels in the blood (at most ~10 times normal) are typical in sIBM but affected individuals can also present with normal CK levels. Electromyography (EMG) studies display variable abnormalities such as increased insertional activity, increased spontaneous activity (fibrillation potentials and sharp waves), and large/broad or short/narrow motor unit potentials. On EMG, recruitment patterns can be reduced or increased. Findings can vary even within the same muscle of an affected individual. Muscle biopsy may display several common findings including inflammatory cells invading muscle cells, vacuolar degeneration, and inclusion bodies of aggregations of multiple proteins. sIBM is a challenge to the pathologist and even with a biopsy, diagnosis can be ambiguous. A diagnosis of inclusion body myositis was historically dependent on muscle biopsy results. Antibodies to cytoplasmic 5'-nucleotidase (cN1A; NT5C1A) have been strongly associated with the condition. However, other inflammatory conditions, such as lupus, can have a positive anti-NT5C1A. As of 2019, it remains to be established whether a positive anti-NT5C1A antibody test can make muscle biopsy unneeded.
Undifferentiated connective tissue disease (UCTD) (also known as latent lupus or incomplete lupus) is a disease in which the connective tissues are targeted by the immune system. It is a serological and clinical manifestation of an autoimmune disease. When there is proof of an autoimmune disease, but the disease does not correspond to any specific autoimmune disease (such as systemic lupus erythematosus (SLE), scleroderma, mixed connective tissue disease, Sjögren syndrome, systemic sclerosis, polymyositis, dermatomyositis, or rheumatoid arthritis), it will be diagnosed as UCTD. This is also the case of major rheumatic diseases whose early phase was defined by LeRoy et al in 1980 as undifferentiated connective tissue disease. The term is sometimes used interchangeably with mixed connective tissue disease (MCTD), as it is an overlap syndrome. However, some researchers believe that MCTD is a clinically distinct entity and is strongly associated with the presence of titer high in antibodies Ribonucleoproteins (RNP). It is estimated that up to 25% of people with systemic autoimmune disease could be considered to have UCTD. There are many people who have features of connective tissue disease, such as blood test results and external characteristics, but do not fulfill the diagnostic criteria established for any one disease. These people are considered to have undifferentiated connective tissue disease (UCTD).
As of January 2018, neither the plant nor its alkaloids were listed in any of the Schedules of the United Nations Drug Conventions. In 2021, the World Health Organization's Executive Committee on Drug Dependency investigated the risks of kratom and declined to recommend a critical review of it. The committee, however, recommended kratom be kept "under surveillance".
=== „Ayda, Bär und Hase“ (2017) === The children's book „Ayda, Bär und Hase“ [Ayda, Bear and Rabbit] revisits the father-daughter relationship motif from the Neil Young book. The father, called Bâbâ, resembles other protagonists in Kermani's books (and the author himself): he has Iranian parents, lives in Cologne, and is a fan of the soccer team 1. FC Cologne and of Neil Young. The focus, however, is now on his five-year-old daughter Ayda, who is ill at ease with her small stature and befriends a bear and a rabbit who can talk. The book’s central themes include multicultural tolerance, the insight “that you can be happy even if not everything is perfect,” and overcoming fears together.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.